EMA Authorised: Rapilysin (reteplase) — Actavis Group PTC ehf

View source ↗

Summary

Rapilysin (reteplase) has been authorised in the EU for myocardial infarction, with Actavis Group PTC ehf as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Rapilysin (reteplase)

Snippet

Status: Authorised. Therapeutic area: Myocardial Infarction. MAH: Actavis Group PTC ehf. Decision date: 31/05/2023